Extended-criteria donors in liver transplantation Part II: reviewing the impact of extended-criteria donors on the complications and outcomes of liver transplantation

Expert Review of Gastroenterology and Hepatology

Volumn 10, Issue 7, 2016, Pages 841-859

  Nemes, Balázs ^a   Gámán, György ^b   Polak, Wojciech G ^c   Gelley, Fanni ^d   Hara, Takanobu ^e   Ono, Shinichiro ^e   Baimakhanov, Zhassulan ^e   Piros, Laszlo ^b   Eguchi, Susumu ^e  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Polyclinic of Hospitallers Brothers of St John of God ^*  (Hungary)

^e NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

biliary complication; extended criteria donor; hepatitis C; initial poor function; ischemia; Liver transplantation; living related transplantation; machine perfusion; recurrence; reperfusion; split liver; survival

Indexed keywords

ANTIVIRUS AGENT;

BILIARY TRACT DISEASE; CLINICAL EFFECTIVENESS; DONOR SELECTION; FATTY LIVER; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT SURVIVAL; HEPATIC ARTERY THROMBOSIS; HEPATITIS C; HUMAN; INFECTION RISK; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REPERFUSION INJURY; REVIEW; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; AGE; CAUSE OF DEATH; DONOR; HEALTH STATUS; HOSPITAL ADMISSION; LIVER FUNCTION TEST; LIVING DONOR; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SUPPLY AND DISTRIBUTION; TIME FACTOR; TREATMENT OUTCOME;

AGE FACTORS; CAUSE OF DEATH; DONOR SELECTION; GRAFT SURVIVAL; HEALTH STATUS; HUMANS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; LIVING DONORS; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TISSUE DONORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 84961210319     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2016.1149062     Document Type: Review

References (137)

1. J.Briceno, R.Ciria, M.De La Mata, et al. Prediction of graft dysfunction based on extended criteria donors in the model for end-stage liver disease score era. Transplantation. 2010;90(5):530–539.
2. H.O.Palmiero, P.Kajikawa, I.F.Boin, et al. Liver recipient survival rate before and after model for end-stage liver disease implementation and use of donor risk index. Transplant Proc. 2010;42(10):4113–4115.
3. G.R.Silberhumer, H.Pokorny, H.Hetz, et al. Combination of extended donor criteria and changes in the model for end-stage liver disease score predict patient survival and primary dysfunction in liver transplantation: a retrospective analysis. Transplantation. 2007;83(5):588–592.
4. P.Schemmer, A.Nickkholgh, U.Hinz, et al. Extended donor criteria have no negative impact on early outcome after liver transplantation: a single-center multivariate analysis. Transplant Proc. 2007;39(2):529–534.
5. R.C.Afonso, R.Hidalgo, A.T.Paes, et al. Impact of cumulative risk factors for expanded criteria donors on early survival after liver transplantation. Transplant Proc. 2008;40(3):800–801.
6. A.W.Avolio, F.Frongillo, N.Nicolotti, et al. Successful use of extended criteria donor grafts with low to moderate steatosis in patients with model for end-stage liver disease scores below 27. Transplant Proc. 2009;41(1):208–212.
7. J.P.Deroose, G.Kazemier, P.Zondervan, et al. Hepatic steatosis is not always a contraindication for cadaveric liver transplantation. HPB (Oxford). 2011;13(6):417–425.
8. A.Nickkholgh, J.Weitz, J.Encke, et al. Utilization of extended donor criteria in liver transplantation: a comprehensive review of the literature. Nephrol Dial Transplant. 2007;22 Suppl 8:viii29–viii36.
9. E.L.De Graaf, J.Kench, P.Dilworth, et al. Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the donor risk index. J Gastroenterol Hepatol. 2012;27(3):540–546.
10. H.M.Noujaim, J.De Ville De Goyet, E.F.Montero, et al. Expanding postmortem donor pool using steatotic liver grafts: a new look. Transplantation. 2009;87(6):919–925.
11. J.Briceno, R.Ciria, M.Pleguezuelo, et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl. 2009;15(1):37–48.•One hundred twenty patients who underwent OLT for HCV cirrhosis between 1995 and 2005 were included in the study. The highlight that HCV recurrence is more frequent and earlier in recipients of moderately and severely steatotic livers.
12. M.B.Doyle, N.Vachharajani, J.R.Wellen, et al. Short- and long-term outcomes after steatotic liver transplantation. Arch Surg. 2010;145(7):653–660.
13. F.Gao, X.Xu, Q.Ling, et al. Efficacy and safety of moderately steatotic donor liver in transplantation. Hepatobiliary Pancreat Dis Int. 2009;8(1):29–33.
14. K.D.Chavin, D.J.Taber, M.Norcross, et al. Safe use of highly steatotic livers by utilizing a donor/recipient clinical algorithm. Clin Transplant. 2013;27(5):732–741.
15. L.McCormack, H.Petrowsky, W.Jochum, et al. Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg. 2007;246(6):940–946. discussion 946-948
16. P.Dutkowski, A.Schlegel, K.Slankamenac, et al. The use of fatty liver grafts in modern allocation systems: risk assessment by the balance of risk (BAR) score. Ann Surg. 2012;256(5):861–868. discussion 868-869
17. K.P.Croome, W.Wall, D.Quan, et al. Evaluation of the updated definition of early allograft dysfunction in donation after brain death and donation after cardiac death liver allografts. Hepatobiliary Pancreat Dis Int. 2012;11(4):372–376.
18. K.M.Olthoff, L.Kulik, B.Samstein, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943–949.
19. B.Nemes, F.Gelley, G.Zadori, et al. Outcome of liver transplantation based on donor graft quality and recipient status. Transplant Proc. 2010;42(6):2327–2330.
20. D.Routh, S.Sharma, C.S.Naidu, et al. Comparison of outcomes in ideal donor and extended criteria donor in deceased donor liver transplant: a prospective study. Int J Surg. 2014;12(8):774–777.
21. F.Suarez, A.Otero, M.Solla, et al. Biliary complications after liver transplantation from maastricht category-2 non-heart-beating donors. Transplantation. 2008;85(1):9–14.
22. J.A.Leithead, L.Tariciotti, B.Gunson, et al. Donation after cardiac death liver transplant recipients have an increased frequency of acute kidney injury. Am J Transplant. 2012;12(4):965–975.
23. B.Nemes, G.Gaman, A.Doros Biliary complications after liver transplantation. Expert Rev Gastroenterol Hepatol. 2015;9(4):447–466.
24. T.Bacchella, F.H.Galvao, J.L.Jesus De Almeida, et al. Marginal grafts increase early mortality in liver transplantation. Sao Paulo Med J. 2008;126(3):161–165.
25. S.Gruttadauria, G.Vizzini, D.Biondo, et al. Critical use of extended criteria donor liver grafts in adult-to-adult whole liver transplantation: a single-center experience. Liver Transpl. 2008;14(2):220–227.
26. H.Le Dinh, A.De Roover, A.Kaba, et al. Donation after cardio-circulatory death liver transplantation. World J Gastroenterol. 2012;18(33):4491–4506.
27. M.Cescon, M.Zanello, G.L.Grazi, et al. Impact of very advanced donor age on hepatic artery thrombosis after liver transplantation. Transplantation. 2011;92(4):439–445.
28. I.Petridis, S.Gruttadauria, S.Nadalin, et al. Liver transplantation using donors older than 80 years: a single-center experience. Transplant Proc. 2008;40(6):1976–1978.
29. J.Campsen, P.Russ, I.Kam. Direct anastomosis of the donor hepatic artery to the supraceliac aorta without extension graft during adult liver transplant in the era of extended criteria donors: report of a case. Case Rep Med. 2010;2010:584631.
30. P.A.Vagefi, J.Parekh, N.L.Ascher, et al. Outcomes with split liver transplantation in 106 recipients: the University of California, San Francisco, experience from 1993 to 2010. Arch Surg. 2011;146(9):1052–1059.•A proper overview about the postoperative graft and patients’ survival, and complications, like biliary (29%), vascular (11%) and PNF, small-for size. The review includes adult and kid program as well.
31. M.Mallik, C.J.Callaghan, M.Hope, et al. Comparison of liver transplantation outcomes from adult split liver and circulatory death donors. Br J Surg. 2012;99(6):839–847.
32. C.Jay, D.Ladner, E.Wang, et al. A comprehensive risk assessment of mortality following donation after cardiac death liver transplant - an analysis of the national registry. J Hepatol. 2011;55(4):808–813.
33. C.L.Jay, V.Luksemburg, D.P.Ladner, et al. Ischemic cholangiopathy after controlled donation after cardiac death liver transplantation: a meta-analysis. Ann Surg. 2011;253(2):259–264.
34. A.I.Skaro, C.L.Jay, T.B.Baker, et al. The impact of ischemic cholangiopathy in liver transplantation using donors after cardiac death: the untold story. Surgery. 2009;146(4):543–552. discussion 552-543
35. S.Yamamoto, H.E.Wilczek, F.F.Duraj, et al. Liver transplantation with grafts from controlled donors after cardiac death: a 20-year follow-up at a single center. Am J Transplant. 2010;10(3):602–611.
36. A.Abou Abbass, M.Abouljoud, A.Yoshida, et al. Biliary complications after orthotopic liver transplantation from donors after cardiac death: broad spectrum of disease. Transplant Proc. 2010;42(9):3392–3398.
37. D.P.Foley, L.A.Fernandez, G.Leverson, et al. Biliary complications after liver transplantation from donation after cardiac death donors: an analysis of risk factors and long-term outcomes from a single center. Ann Surg. 2011;253(4):817–825.••A retrospective review of 1157 “donation after brain death” (DBD) and 87 DCD liver transplants. Multivariate analysis revealed that cold ischemic time (CIT) greater than 8 hours (HR: 2.46; P = 0.05) and donor age greater than 40 years (HR: 2.90; P < 0.01) significantly increased the risk of ischemic cholangiopathy.
38. M.L.De Oliveira, W.Jassem, R.Valente, et al. Biliary complications after liver transplantation using grafts from donors after cardiac death: results from a matched control study in a single large volume center. Ann Surg. 2011;254(5):716–722. discussion 722-713
39. S.J.Wigmore. Current challenges in liver transplantation following donation after cardiac death. Transplantation. 2010;90(10):1048–1049.
40. R.Lopez-Andujar, E.M.Montala, F.A.Vergara. Reply to letter: “A question seeking for an answer: use of t-tube in the era of liver transplantation with grafts from extended criteria donors and donors after cardiac death”. Ann Surg. 2015;261(6):174–175.
41. D.Moris, G.C.Sotiropoulos, S.Vernadakis. A question seeking for an answer: use of t-tube in the era of liver transplantation with grafts from extended criteria donors and donors after cardiac death. Ann Surg. 2015;261(6):173–174.
42. R.Lopez-Andujar, E.M.Oron, A.F.Carregnato, et al. T-tube or no T-tube in cadaveric orthotopic liver transplantation: the eternal dilemma: results of a prospective and randomized clinical trial. Ann Surg. 2013;258(1):21–29.
43. E.Y.Chan, L.C.Olson, J.A.Kisthard, et al. Ischemic cholangiopathy following liver transplantation from donation after cardiac death donors. Liver Transpl. 2008;14(5):604–610.
44. U.Baccarani, M.Isola, G.L.Adani, et al. Steatosis of the hepatic graft as a risk factor for post-transplant biliary complications. Clin Transplant. 2010;24(5):631–635.
45. C.Fondevilla, A.J.Hessheimer, E.Flores, et al. Applicability and results of Maastricht type 2 donation after cardiac death liver transplantation. Am J Transplant. 2012;12(1):162–170.
46. D.Monbaliu, J.Pirenne, D.Talbot. Liver transplantation using Donation after cardiac death donors. J Hepatol. 2012;56(2):474–485.
47. V.Subramanian, A.B.Seetharam, N.Vachharajani, et al. Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation. Transplantation. 2011;92(11):1259–1268.
48. G.Yagci, L.A.Fernandez, S.J.Knechtle, et al. The impact of donor variables on the outcome of orthotopic liver transplantation for hepatitis C. Transplant Proc. 2008;40(1):219–223.
49. R.Hernandez-Alejandro, K.P.Croome, D.Quan, et al. Increased risk of severe recurrence of hepatitis C virus in liver transplant recipients of donation after cardiac death allografts. Transplantation. 2011;92(6):686–689.
50. C.B.Taner, I.G.Bulatao, A.P.Keaveny, et al. Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus. Liver Transpl. 2011;17(6):641–649.
51. T.Uemura, V.Ramprasad, C.S.Hollenbeak, et al. Liver transplantation for hepatitis C from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant. 2012;12(4):984–991.•630 HCV, 1164 non-HCV and 54 129 donation after brain death (DBD) liver transplantation between 2002 and 2009 using the UNOS/OPTN database were evaluated. DCD liver transplantation for HCV disease showed satisfactory outcomes.
52. R.Tao, K.Ruppert, R.J.CruzJr., et al. Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts. Liver Transpl. 2010;16(11):1288–1295.
53. P.G.Northup, C.K.Argo, D.T.Nguyen, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US national transplant registry analysis. Transpl Int. 2010;23(10):1038–1044.
54. R.Ballarin, A.Cucchetti, M.Spaggiari, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation. 2011;91(11):1265–1272.
55. A.T.Burra, Y.Li, J.F.Tseng, et al. Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database. World J Surg. 2011;35(7):1590–1595.
56. J.G.O’Leary, M.A.Neri, J.F.Trotter, et al. Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined. Transpl Int. 2012;25(8):825–829.
57. L.Yu, T.Koepsell, L.Manhart, et al. Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor. Liver Transpl. 2009;15(10):1343–1350.
58. M.P.MacConmara, N.Vachharajani, J.R.Wellen, et al. Utilization of hepatitis B core antibody-positive donor liver grafts. HPB (Oxford). 2012;14(1):42–48.
59. M.Angelico, A.Nardi, T.Marianelli, et al. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the liver match cohort study. J Hepatol. 2013;58(4):715–723.•1437 consecutive, first transplants were analyzed. Of these, 219 (15.2%) were HBcAb positive. 66 HBcAb positive grafts were allocated to HBsAg positive and 153 to HBsAg negative recipients. HBcAb positive donor grafts have better outcomes when transplanted into HBsAg positive than HBsAg negative recipients.
60. V.Lucidi, A.C.Lemye, L.Baire, et al. Use of marginal donors for liver transplantation: a single-center experience within the Eurotransplant patient-driven allocation system. Transplant Proc. 2007;39(8):2668–2671.
61. A.K.Burroughs, C.A.Sabin, K.Rolles, et al. 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet. 2006;367(9506):225–232.
62. A.K.Mathur, J.Heimbach, D.E.Steffick, et al. Donation after cardiac death liver transplantation: predictors of outcome. Am J Transplant. 2010;10(11):2512–2519.
63. O.Nafidi, D.Marleau, A.Roy, et al. Identification of new donor variables associated with graft survival in a single-center liver transplant cohort. Liver Transpl. 2010;16(12):1393–1399.
64. M.T.Serrano, A.Garcia-Gil, J.Arenas, et al. Outcome of liver transplantation using donors older than 60 years of age. Clin Transplant. 2010;24(4):543–549.
65. D.Y.Kim, J.Moon, E.R.Island, et al. Liver transplantation using elderly donors: a risk factor analysis. Clin Transplant. 2011;25(2):270–276.
66. D.Ghinolfi, J.Marti, P.De Simone, et al. Use of octogenarian donors for liver transplantation: a survival analysis. Am J Transplant. 2014;14(9):2062–2071.
67. D.P.Hoyer, A.Paul, F.Saner, et al. Safely expanding the donor pool: brain dead donors with history of temporary cardiac arrest. Liver Int. 2015;35(6):1756–1763.
68. J.Briceno, R.Ciria, M.Pleguezuelo, et al. Contribution of marginal donors to liver transplantation for hepatitis C virus infection. Transplant Proc. 2007;39(7):2297–2299.
69. N.Yilmaz, M.L.Shiffman. Impact of the donor liver with steatosis in patients with hepatitis C virus: not so FAst. Liver Transpl. 2009;15(1):4–6.
70. T.Uemura, L.E.Nikkel, C.S.Hollenbeak, et al. How can we utilize livers from advanced aged donors for liver transplantation for hepatitis C? Transpl Int. 2012;25(6):671–679.
71. D.Balfoussia, D.Yerrakalva, K.Hamaoui, et al Advances in machine perfusion graft viability assessment in kidney, liver, pancreas, lung, and heart transplant. Exp Clin Transplant. 2012;10(2):87–100.
72. M.Wali, R.F.Harrison, P.J.Gow, et al. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut. 2002;51(2):248–252.
73. J.F.Botha, E.Thompson, R.Gilroy, et al. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int. 2007;27(6):758–763.
74. P.Thiagarajan, S.D.Ryder. The hepatitis C revolution part 1: antiviral treatment options. Curr Opin Infect Dis. 2015;28(6):563–571.
75. S.-G.Lee. A complete treatment of adult living donor liver transplantation: a review of surgical technique and current challenges to expand indication of patients. Am J Transplant. 2015;15(1):17–38.
76. C.Hackl, H.J.Schlitt, M.Melter, et al. Current developments in pediatric liver transplantation. World J Hepatol. 2015;7(11):1509–1520.
77. J.Mittler, A.Pascher, P.Neuhaus, et al. The utility of extended criteria donor organs in severely ill liver transplant recipients. Transplantation. 2008;86(7):895–896.
78. S.Gordon Burroughs, R.W.Busuttil. Optimal utilization of extended hepatic grafts. Surg Today. 2009;39(9):746–751.
79. T.R.Harring, N.T.Nguyen, R.T.Cotton, et al. Liver transplantation with donation after cardiac death donors: a comprehensive update. J Surg Res. 2012;178(1):502–511.••The comprehensive evaluation of 85,148 patients received hepatic allografts from donation-after-brain-death (DBD) donors, and 2351 patients received hepatic allografts from DCD donors. Pediatric patients who received a hepatic DCD allograft had similar survival to those who received a hepatic DBD allograft.
80. J.J.Blok, A.E.Braat, R.Adam, et al. Validation of the donor risk index in orthotopic liver transplantation within the Eurotransplant region. Liver Transpl. 2012;18(1):112–119.
81. N.R.Barshes, I.B.Horwitz, L.Franzini, et al. Waitlist mortality decreases with increased use of extended criteria donor liver grafts at adult liver transplant centers. Am J Transplant. 2007;7(5):1265–1270.
82. P.L.Abt, N.M.Desai, M.D.Crawford, et al. Survival following liver transplantation from non-heart-beating donors. Ann Surg. 2004;239(1):87–92.
83. J.H.Nguyen, H.Bonatti, R.C.Dickson, et al. Long-term outcomes of donation after cardiac death liver allografts from a single center. Clin Transplant. 2009;23(2):168–173.
84. S.Feng, N.P.Goodrich, J.L.Bragg-Gresham, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. 2006;6(4):783–790.
85. J.Briceno, R.Ciria, M.De La Mata, et al. Extended criteria donors in liver transplant candidates with hepatorenal syndrome. Clin Transplant. 2011;25(3):E257–263.
86. W.-C.Lee, K.-M.Chan, H.-S.Chou, et al. Feasibility of split liver transplantation for 2 adults in the model of end-stage liver disease era. Ann Surg. 2013;258(2):306–311.••Twenty-one deceased liver grafts were split into full right and full left lobes for 42 adult recipients, and compared to living related. The 1-, 3-, and 5-year survival rates for split liver transplantation were comparable with those of living donor transplantation (P = 0.489).
87. R.P.Cauley, K.Vakili, N.Fullington, et al. Deceased-donor split-liver transplantation in adult recipients: is the learning curve over? J Am Coll Surg. 2013;217(4):672–684.e671.
88. M.Berenguer. Risk of extended criteria donors in hepatitis C virus-positive recipients. Liver Transpl. 2008;14 Suppl 2:S45–50.
89. J.R.Lake, J.S.Shorr, B.J.Steffen, et al. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant. 2005;5(3):549–557.
90. M.Ghabril, R.C.Dickson, M.Krishna, et al. Liver transplantation using young pediatric donor grafts in adults with hepatitis C infection. Transplantation. 2009;87(8):1174–1179.
91. P.Burra, M.Loreno, F.P.Russo, et al. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl. 2009;15(6):619–628.
92. A.C.Baltz, J.F.Trotter. Living donor liver transplantation and hepatitis C. Clin Liver Dis. 2003;7(3):651–665, viii.
93. M.Dall’Agata, A.Gramenzi, M.Biselli, et al. Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents? World J Gastroenterol. 2014;20(28):9253–9260.
94. S.Pungpapong, B.A.Aqel, L.Koning, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013;19,:690–700.
95. A.Coilly, J.Dumortier, D.Botta-Fridlund, et al. Multicenter experience with boceprevir or telaprevir to treat Hepatitis C recurrence after liver transplantation: when present becomes past, what lessons for future? PLoS ONE. 2015;10(9):e0138091. doi:10.1371/journal.pone.0138091.
96. M.Charlton, E.Gane, M.P.Manns, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis c virus infection after liver transplantation. Gastroenterology. 2015;148:108–117.
97. L.L.Seifert, E.Vorona, C.Bester, et al. Interferon-free sofosbuvir-based Anti-HCV therapy after liver transplantation. Ann Transplant. 2015;20:561–568.
98. M.Gastaca. Extended criteria donors in liver transplantation: adapting donor quality and recipient. Transplant Proc. 2009;41(3):975–979.
99. M.K.Angele, M.Rentsch, W.H.Hartl, et al. Effect of graft steatosis on liver function and organ survival after liver transplantation. Am J Surg. 2008;195(2):214–220.
100. P.G.Northup, T.L.Pruett, D.M.Kashmer, et al. Donor factors predicting recipient survival after liver retransplantation: the retransplant donor risk index. Am J Transplant. 2007;7(8):1984–1988.
101. J.Marti, J.Fuster, M.Navasa, et al. Effects of graft quality on non-urgent liver retransplantation survival: should we avoid high-risk donors? World J Surg. 2012;36(12):2914–2922.
102. D.Monbaliu, Q.Liu, L.Libbrecht, et al. Preserving the morphology and evaluating the quality of liver grafts by hypothermic machine perfusion: a proof-of-concept study using discarded human livers. Liver Transpl. 2012;18(12):1495–1507.
103. J.S.Kim, D.C.Broering, R.Y.Tustas, et al. Split liver transplantation: past, present and future. Pediatr Transplant. 2004;8(6):644–648.
104. D.C.Broering, L.Mueller, R.Ganschow, et al. Is there still a need for living-related liver transplantation in children? Ann Surg. 2001;234(6):713–721. discussion 721-712
105. E.L.Decoster, R.Troisi, M.Sainz-Barriga, et al. Improved results for adult split liver transplantation with extended right lobe grafts: could we enhance its application? Transplant Proc. 2009;41(8):3403–3406.
106. U.Maggi, T.M.DeFeo, E.Andorno, et al. Fifteen years and 382 extended right grafts from in situ split livers in a multicenter study: are these still extended criteria liver grafts? Liver Transpl. 2015;21(4):500–511.•A very large study incorportating the results of 9 centres between 1997 and 2011, impressive numbers: including 382 in situ split liver extended right grafts transplants in adults. From 2005 to 2011, in 2473 LTs, the 5-year graft survival for 184 in situ SL-ERGs and 2289 whole grafts was 75% and 80% (P=0.3), respectively.
107. C.L.Jay, A.I.Skaro, D.P.Ladner, et al. Comparative effectiveness of donation after cardiac death versus donation after brain death liver transplantation: Recognizing who can benefit. Liver Transpl. 2012;18(6):630–640.
108. P.Wan, Q.Li, J.Zhang, et al. Right lobe split liver transplantation versus whole liver transplantation in adult recipients: A systematic review and meta-analysis. Liver Transpl. 2015;21(7):928–943.
109. M.Zambelli, E.Andorno, L.De Carlis, et al. Full-right-full-left split liver transplantation: the retrospective analysis of an early multicenter experience including graft sharing. Am J Transplant. 2012;12(8):2198–2210.
110. P.Aseni, T.M.De Feo, L.De Carlis, et al. A prospective policy development to increase split-liver transplantation for 2 adult recipients: results of a 12-year multicenter collaborative study. Ann Surg. 2014;259(1):157–165.•A relevant paper about adult-to adult LTs. Authors report a computerized algorhythm in selected donors for two adult recipients, and applied it for 12 years in 7 centres.
111. H.Obara, N.Matsuno, T.Shigeta, et al. Temperature controlled machine perfusion system for liver. Transplant Proc. 2013;45(5):1690–1692.
112. P.Dutkowski, A.Schlegel, M.De Oliveira, et al. HOPE for human liver grafts obtained from donors after cardiac death. J Hepatol. 2014;60(4):765–772.••This is the first report on cold machine perfusion of human liver grafts obtained after cardiac arrest and subsequent transplantation. Application of HOPE appears well tolerated, easy-to-use, and protective against early and later injuries.
113. M.Bessems, B.M.Doorschodt, J.L.Kolkert, et al. Preservation of steatotic livers: a comparison between cold storage and machine perfusion preservation. Liver Transpl. 2007;13(4):497–504.
114. A.Franchello, N.Gilbo, E.David, et al. Ischemic preconditioning (IP) of the liver as a safe and protective technique against ischemia/reperfusion injury (IRI). Am J Transplant. 2009;9(7):1629–1639.•Ischaemic preconditioning of the liver has a positive hepatoprotective effect. During the procurement procedure authors performed 10-min inflow occlusion followed by 30min of reperfusion prior to the start of cold ischemia.
115. P.Olschewski, P.Gass, V.Ariyakhagorn, et al. The influence of storage temperature during machine perfusion on preservation quality of marginal donor livers. Cryobiology. 2010;60(3):337–343.
116. M.Schmeding, S.Rademacher, S.Boas-Knoop, et al. rHuEPo reduces ischemia-reperfusion injury and improves survival after transplantation of fatty livers in rats. Transplantation. 2010;89(2):161–168.
117. R.S.Mangus, J.A.Fridell, R.M.Vianna, et al. Comparison of histidine-tryptophan-ketoglutarate solution and University of Wisconsin solution in extended criteria liver donors. Liver Transpl. 2008;14(3):365–373.
118. C.Bae, S.D.Henry, J.V.Guarrera. Is extracorporeal hypothermic machine perfusion of the liver better than the ‘good old icebox’? Curr Opin Organ Transplant. 2012;17(2):137–142.
119. P.Dutkowski, O.De Rougemont, P.-A.Clavien. Machine perfusion for ‘marginal’ liver grafts. Am J Transplant. 2008;8(5):917–924.
120. A.Schlegel, P.Kron, R.Graf, et al. Hypothermic Oxygenated Perfusion (HOPE) downregulates the immune response in a rat model of liver transplantation. Ann Surg. 2014;260(5):931–937. discussion 937-938
121. K.Vekemans, Q.Liu, J.Pirenne, et al. Artificial circulation of the liver: machine perfusion as a preservation method in liver transplantation. Anat Rec (Hoboken). 2008;291(6):735–740.
122. O.De Rougemont, S.Breitenstein, B.Leskosek, et al. One hour hypothermic oxygenated perfusion (HOPE) protects nonviable liver allografts donated after cardiac death. Ann Surg. 2009;250(5):674–683.•Authors demonstrated that a short term 1 hour hypothermic oxygenated perfusion might lead to histological and functional liver improvement after DCD livers.
123. J.Stegemann, A.Hirner, U.Rauen, et al. Use of a new modified HTK solution for machine preservation of marginal liver grafts. J Surg Res. 2010;160(1):155–162.
124. T.Vogel, J.G.Brockmann, P.J.Friend. Ex-vivo normothermic liver perfusion: an update. Curr Opin Organ Transplant. 2010;15(2):167–172.
125. J.V.Guarrera, S.D.Henry, B.Samstein, et al. Hypothermic machine preservation in human liver transplantation: the first clinical series. Am J Transplant. 2010;10(2):372–381.••The first prospective liver HMP study, 20 adults received HMP-preserved livers and were compared to a matched group transplanted with CS livers.
126. J.E.Tulipan, J.Stone, B.Samstein, et al. Molecular expression of acute phase mediators is attenuated by machine preservation in human liver transplantation: preliminary analysis of effluent, serum, and liver biopsies. Surgery. 2011;150(2):352–360.
127. J.V.Guarrera. Assist devices: machine preservation of extended criteria donors. Liver Transpl. 2012;18 Suppl 2:S31–33.
128. R.Flisiak. Role of Ito cells in the liver function. Polish Journal of Pathology: Official Journal of the Polish Society of Pathologists. 1997;48(3):139–145.
129. J.Lambrecht, I.Mannaerts, L.A.Van Grunsven. The role of miRNAs in stress-responsive hepatic stellate cells during liver fibrosis. Front Physiol. 2015;6:209.
130. A.Florimond, P.Chouteau, P.Bruscella, et al., et al. Human hepatic stellate cells are not permissive for hepatitis C virus entry and replication. Gut. 2015;64(6):957–965.
131. A.S.Gouw, A.D.Clouston, N.D.Theise. Ductular reactions in human liver: diversity at the interface. Hepatology. 2011;54(5):1853–1863.
132. E.Prakoso, J.E.Tirnitz-Parker, A.D.Clouston, et al. Analysis of the intrahepatic ductular reaction and progenitor cell responses in hepatitis C virus recurrence after liver transplantation. Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2014;20(12):1508–1519.
133. J.C.Hong, H.Yersiz, P.Kositamongkol, et al. Liver transplantation using organ donation after cardiac death: a clinical predictive index for graft failure-free survival. Arch Surg. 2011;146(9):1017–1023.
134. F.W.Selck, E.B.Grossman, L.E.Ratner, et al. Utilization, outcomes, and retransplantation of liver allografts from donation after cardiac death: implications for further expansion of the deceased-donor pool. Ann Surg. 2008;248(4):599–607.
135. P.Bruzzone, D.Giannarelli, R.Adam. A preliminary European Liver and Intestine Transplant Association-European Liver Transplant Registry study on informed recipient consent and extended criteria liver donation. Transplant Proc. 2013;45(7):2613–2615.
136. N.Nemeth, F.Kiss, T.Hever, et al. Hemorheological consequences of hind limb ischemia-reperfusion differs in normal and gonadectomized male and female rats. Clin Hemorheol Microcirc. 2012;50(3):197–211.•The authors in their in vivo experiment analysed the different hematological parameters in twenty-five male and twenty-five female Sprague-Dawley rats. After hind-limb ischemia-reperfusion and gonadectomy the results showed gender differences in rats, reflecting significant impairment of red blood cell deformability on the 1st–3rd postoperative day, and raised aggregation index values in males.
137. N.Nemeth, I.Furka, I.Miko. Hemorheological changes in ischemia-reperfusion: an overview on our experimental surgical data. Clin Hemorheol Microcirc. 2014;57(3):215–225.